Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial

Aptose Biosciences Inc.

100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).
78% MRD-negativity among responders (7/9); 100% MRD-negativity in TP53, RAS, FLT3-ITD subgroups.
No dose-limiting toxicities or prolonged myelosuppression; enrollment advancing to 160 mg cohort.
Single non-responder was at 40 mg dose with subtherapeutic TUS exposure; all other patients remain on study.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.